What is Gilead Sciences?
Biopharmaceuticals company with $29.4B 2025 revenue scale and public-market buying capacity.
- Category
- Biopharmaceuticals
- Headquarters
- Foster City, CA
- Founded
- 1987
- Employees
- 18,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: GILD; Public company
What is Gilead Sciences?
Gilead Sciences is a public biopharmaceuticals company headquartered in Foster City, CA. Gilead reported total full-year 2025 revenues of $29.4 billion, including $28.9 billion of product sales led by HIV.
Gilead Sciences operates in biopharmaceuticals with a portfolio that includes Biktarvy, Descovy, Lenacapavir, Yescarta. Gilead reported total full-year 2025 revenues of $29.4 billion, including $28.9 billion of product sales led by HIV. The company employs about 18,000+ and trades as Nasdaq: GILD, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Gilead Sciences through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Gilead Sciences is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Gilead Sciences offer?
Gilead Sciences offers products and services across Biktarvy, Descovy, Lenacapavir, Yescarta and related healthcare workflows.
- Biktarvy· HIV
- Descovy· HIV prevention
- Lenacapavir· HIV
- Yescarta· Cell therapy
- Trodelvy· Oncology
- Livdelzi· Liver disease
How does Gilead Sciences make money?
Gilead Sciences earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Gilead Sciences earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $29.4B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Gilead Sciences improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Gilead Sciences?
Gilead Sciences is led by Daniel O'Day, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Daniel O'DayChairman and Chief Executive OfficerCEO since 2019Leads Gilead's HIV franchise, oncology expansion, and capital allocation.
- Andrew DickinsonChief Financial OfficerCFO since 2019Oversees finance, corporate development, and investor planning.
- Dietmar BergerChief Medical OfficerCMO in 2026Guides clinical development across virology, oncology, and inflammation.
- Johanna MercierChief Commercial OfficerSenior commercial leaderRuns global commercial strategy and launch execution.
How do you contact Gilead Sciences's leadership?
Gilead Sciences publishes official Gilead investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Gilead investor-relations contact route; personal executive email format not verifiedHow much funding has Gilead Sciences raised?
Gilead Sciences is a mature public company, not a venture-backed startup. It trades as Nasdaq: GILD and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Gilead Sciences's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: GILD, $29.4B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Gilead Sciences has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Gilead Sciences get here?
Gilead Sciences grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1987Gilead foundedThe company begins in the San Francisco Bay Area.
- 1992IPOGilead becomes a public biotechnology company.
- 2017Kite acquisitionGilead enters cell therapy at scale through Kite.
- 2020Trodelvy acquisitionGilead expands oncology with Immunomedics.
- 2025$29.4B revenueGilead reports total full-year 2025 revenues of $29.4 billion.
- 2026HIV growth continuesQ1 2026 product sales rise with HIV, Trodelvy, and Livdelzi contribution.
Who are Gilead Sciences's competitors?
Gilead Sciences competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- ViiV HealthcareCompetes most directly in HIV treatment and prevention.
- Merck & Co.Competes in HIV, oncology, and hospital infectious-disease portfolios.
- Bristol Myers SquibbCompetes in oncology, cell therapy, and specialty-care access.
- AbbVieCompetes in immunology, oncology, virology legacy areas, and specialty pharmacy.
- Johnson & JohnsonCompetes in oncology, immunology, and infectious disease.
- RocheCompetes in oncology and diagnostics-linked specialty care.
Gilead Sciences — frequently asked questions
